We are proud to highlight the outstanding performance of Associate Prof. Dr. Adlinda Alip, Study Coordinator Ms. Suganiya Rama Rao and the team at Universiti Malaya Medical Centre (UMMC) in the ASCENT-03 and ASCENT-04 trials. These pivotal studies focus on improving treatment options for patients with locally advanced, inoperable, or metastatic triple-negative breast cancer (TNBC), a challenging and aggressive form of cancer.
UMMC’s Outstanding Achievements
For ASCENT-03, activated on 21 January 2024, UMMC surpassed expectations by randomizing 4 subjects within just four months, closing recruitment on 31 May 2024. This achievement secured UMMC’s position as the top enroller in Malaysia and Southeast Asia.
In ASCENT-04, also activated on 21 January 2024, the team met its target by randomizing 3 subjects in 5.5 months, with recruitment concluding on 3 July 2024. Once again, UMMC was recognized as the top enroller in the region.
A Testament to Excellence
These accomplishments reflect the team’s dedication, efficiency, and expertise in delivering high-quality clinical trial outcomes within tight timelines. We extend our deepest appreciation to Prof. Adlinda and her team for their pivotal role in advancing clinical research and improving patient care.
We look forward to continuing our successful collaboration and achieving more milestones together in the future.